The United Bio-Technology (Hengqin) Co. Ltd. has reported compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of diabetes type 1, gout, psoriasis, stroke, inflammatory bowel disease, hyperlipidemia, and Alzheimer’s and Parkinson’s disease, among others.
Di’ao Group Chengdu Pharmaceutical Co. Ltd. has synthesized glucagon-like peptide-1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of hypertension, diabetes type 1, cerebral infarction, metabolic dysfunction-associated steatohepatitis (MASH; NASH), metabolic syndrome, obesity, arteriosclerosis and Parkinson’s disease, among others.
Novo Nordisk A/S has disclosed GLP-1 polypeptide analogues acting as glucagon-like peptide-1 receptor (GLP-1R) agonists. As such, they are reported to be useful for the treatment of obesity and diabetes.
Chong Kun Dang Pharmaceutical Corp. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of cardiovascular, endocrine, immunological, psychiatric, renal, inflammatory disorders, metabolic diseases and neurodegeneration.
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Fortvita Biologics Inc. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, inflammatory disorders, diabetes, lung diseases, neurological disorders, obesity and renal disorders, among others.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described compounds acting as gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonists reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD, NAFLD), diabetes and obesity.
